Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 442

1.

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.

Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D.

Clin Pharmacokinet. 2019 Jun 18. doi: 10.1007/s40262-019-00788-8. [Epub ahead of print]

PMID:
31209657
2.

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I.

Haematologica. 2019 Jun 6. pii: haematol.2019.220590. doi: 10.3324/haematol.2019.220590. [Epub ahead of print]

3.

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.

Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD.

Lancet Haematol. 2019 May 17. pii: S2352-3026(19)30085-7. doi: 10.1016/S2352-3026(19)30085-7. [Epub ahead of print]

PMID:
31109827
4.

REMOVED: Safety Is the Heart of the Matter.

Campbell BA, Seymour JF.

Int J Radiat Oncol Biol Phys. 2019 Apr 23. pii: S0360-3016(19)30248-2. doi: 10.1016/j.ijrobp.2019.02.022. [Epub ahead of print] No abstract available.

PMID:
31027909
5.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Apr 25. pii: blood.2018882555. doi: 10.1182/blood.2018882555. [Epub ahead of print]

PMID:
31023700
6.

The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials.

Russell L, Pascoe MC, Seymour JF, Aranda S, Butow P, Gough K, Schofield P.

BMC Res Notes. 2019 Apr 15;12(1):226. doi: 10.1186/s13104-019-4264-6.

7.

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.

Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, Marcus R, Hiddemann W, Seymour JF, Strefford JC, Hargreaves CE, Meneses-Lorente G, Frey N, Fingerle-Rowson G.

Br J Clin Pharmacol. 2019 Mar 13. doi: 10.1111/bcp.13920. [Epub ahead of print]

PMID:
30866056
8.

Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression.

Slavin MA, Worth LJ, Seymour JF, Thursky KA.

J Clin Oncol. 2019 May 1;37(13):1139-1140. doi: 10.1200/JCO.18.01474. Epub 2019 Mar 7. No abstract available.

PMID:
30844318
9.

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.

Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W.

Haematologica. 2019 Jun;104(6):1202-1208. doi: 10.3324/haematol.2018.209015. Epub 2018 Dec 20.

10.

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.

Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Leuk Lymphoma. 2019 Apr;60(4):904-911. doi: 10.1080/10428194.2018.1516873. Epub 2018 Dec 14.

PMID:
30547695
11.

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF.

Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13.

12.

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ.

J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3.

13.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
14.

Reply to M. Sorigue et al.

MacManus M, Fisher R, McClure B, Seymour JF.

J Clin Oncol. 2019 Jan 20;37(3):257-258. doi: 10.1200/JCO.2018.18.01309. Epub 2018 Nov 26. No abstract available.

PMID:
30475669
15.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ.

Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.

PMID:
30455436
16.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
17.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG).

Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12.

PMID:
30315232
18.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.

19.

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies.

Tiong IS, Reynolds J, Bradstock KF, Seymour JF, Wei AH; Australasian Leukaemia & Lymphoma Group.

Blood Cancer J. 2018 Aug 22;8(9):84. doi: 10.1038/s41408-018-0121-4. No abstract available.

20.

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission.

Rady K, Blombery P, Westerman DA, Wall M, Curtis M, Campbell LJ, Seymour JF.

Leuk Res. 2018 Oct;73:1-4. doi: 10.1016/j.leukres.2018.08.010. Epub 2018 Aug 16.

PMID:
30170269
21.

Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone.

Ng SP, Khor R, Bressel M, MacManus M, Seymour JF, Hicks RJ, Wirth A.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):80-86. doi: 10.1007/s00259-018-4112-2. Epub 2018 Aug 7.

PMID:
30083824
22.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.

J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.

23.

Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.

MacManus M, Fisher R, Roos D, O'Brien P, Macann A, Davis S, Tsang R, Christie D, McClure B, Joseph D, Jayamohan J, Seymour JF.

J Clin Oncol. 2018 Oct 10;36(29):2918-2925. doi: 10.1200/JCO.2018.77.9892. Epub 2018 Jul 5.

PMID:
29975623
24.

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.

Kim SK, Knight DA, Jones LR, Vervoort S, Ng AP, Seymour JF, Bradner JE, Waibel M, Kats L, Johnstone RW.

Genes Dev. 2018 Jun 1;32(11-12):849-864. doi: 10.1101/gad.307504.117. Epub 2018 Jun 15.

25.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM.

Lancet Haematol. 2018 Nov;5(11):e563-e598. doi: 10.1016/S2352-3026(18)30051-6. Epub 2018 Jun 18. Review. Erratum in: Lancet Haematol. 2019 Mar;6(3):e121.

26.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.

Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.

PMID:
29897404
27.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

PMID:
29895707
28.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
29.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF.

J Clin Oncol. 2018 Sep 1;36(25):2657-2658. doi: 10.1200/JCO.2018.78.6137. Epub 2018 May 31. No abstract available.

PMID:
29851544
30.

Venetoclax-Rituximab in Chronic Lymphocytic Leukemia.

Seymour JF, Mobasher M, Kater AP.

N Engl J Med. 2018 May 31;378(22):2143-2144. doi: 10.1056/NEJMc1805135. No abstract available.

PMID:
29847765
31.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.

PMID:
29715056
32.

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G.

Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.

PMID:
29666118
33.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

34.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

35.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Review.

36.

Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas.

Stathis A, Iasonos A, Seymour JF, Thieblemont C, Ribrag V, Zucca E, Younes A.

Clin Cancer Res. 2018 Jul 1;24(13):2993-2998. doi: 10.1158/1078-0432.CCR-17-3021. Epub 2018 Mar 13.

PMID:
29535129
37.

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D.

Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21.

38.

Obinutuzumab Treatment of Follicular Lymphoma.

Marcus R, Seymour JF, Hiddemann W.

N Engl J Med. 2017 Dec 28;377(26):2605-2606. doi: 10.1056/NEJMc1714337. No abstract available.

PMID:
29281572
39.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.

BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.

40.

Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.

Pereira-Salgado A, Westwood JA, Russell L, Ugalde A, Ortlepp B, Seymour JF, Butow P, Cavedon L, Ong K, Aranda S, Breen S, Kirsa S, Dunlevie A, Schofield P.

JMIR Mhealth Uhealth. 2017 Dec 6;5(12):e184. doi: 10.2196/mhealth.8349.

41.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W.

N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.

42.

Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients.

Oberoi DV, White VM, Seymour JF, Prince HM, Harrison S, Jefford M, Winship I, Hill DJ, Bolton D, Millar J, Wong Doo N, Kay A, Giles G.

Eur J Haematol. 2017 Nov;99(5):423-430. doi: 10.1111/ejh.12941. Epub 2017 Oct 9.

PMID:
28833529
43.

Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.

Ryland GL, Jones K, McBean M, Khot A, Seymour JF, Blombery P.

Leuk Lymphoma. 2018 Apr;59(4):992-995. doi: 10.1080/10428194.2017.1361029. Epub 2017 Aug 9. No abstract available.

PMID:
28792266
44.

Azacitidine in adult patients with acute myeloid leukemia.

Schuh AC, Döhner H, Pleyer L, Seymour JF, Fenaux P, Dombret H.

Crit Rev Oncol Hematol. 2017 Aug;116:159-177. doi: 10.1016/j.critrevonc.2017.05.010. Epub 2017 Jun 3. Review.

PMID:
28693797
45.

The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers.

Oberoi D, White VM, Seymour JF, Miles Prince H, Harrison S, Jefford M, Winship I, Hill D, Bolton D, Kay A, Millar J, Doo NW, Giles G.

Support Care Cancer. 2017 Nov;25(11):3447-3456. doi: 10.1007/s00520-017-3766-9. Epub 2017 Jun 30.

PMID:
28667564
46.

Patient perceptions of treatment-free remission in chronic myeloid leukemia.

Villemagne Sanchez LA, O'Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF, Schofield P, Ross DM.

Leuk Lymphoma. 2018 Feb;59(2):406-415. doi: 10.1080/10428194.2017.1337114. Epub 2017 Jun 15.

PMID:
28617066
47.

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS.

Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Review.

PMID:
28504030
48.

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Butler LA, Tam CS, Seymour JF.

Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Review.

PMID:
28499646
49.

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW.

Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4.

50.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

Supplemental Content

Loading ...
Support Center